D’Ortenzio E, Lemaître N, Brouat C, Loubet P, Sebbane F, Rajerison M, Baril L, Yazdanpanah Y.
The INRB of Kinshasa and Inserm have identified the Ebola Zaire strain as responsible for the epidemic currently raging in the DRC.
“Our experience in Guinea during the 2014 Ebola outbreak, the REACTing platform under the responsibility of Prof. Yazdanpanah, and the North / South collaborations put in place allowed us to better prepare and respond quickly”, says Pr Yves Lévy, CEO of Inserm.
A study conducted in pregnant women and their unborn children during the Zika epidemic in the French territories in the Americas, permitted researchers from Inserm, Institut Pasteur and the University Hospital of Guadeloupe to accurately estimate the risk of severe neurological complications in babies. They have also determined that the first trimester of pregnancy is the period with the highest risk. While the overall risk is 7%, this rises to 12.7% – i.e. more than 1 in 10 children – if infection occurs during the first 3 months of pregnancy. Published in the New England Journal of Medicine.
The Partnership for Research on Ebola VACcination (PREVAC) immunisation study began 1 year ago, when the Ebola virus was re-emerging in the DRC. Thanks to more than 2,000 adults and children in the study in Guinea and Liberia, this international clinical trial is evaluating the safety and immunogenicity of two potential vaccines against the Ebola virus. The results will be decisive in preventing a new epidemic.
Ebola, état des lieux des projets de recherche menés dans le cadre de REACTing en 2015
Simonin Y, van Riel D, Van de Perre P, Rockx B, Salinas S.
Joguet G, Mansuy JM, Matusali G, Hamdi S, Walschaerts M, Pavili L, Guyomard S, Prisant N, Lamarre P, Dejucq-Rainsford N, Pasquier C, Bujan L.
Etard JF, Sow MS, Leroy S, Touré A, Taverne B, Keita AK, Msellati P, Magassouba N, Baize S, Raoul H, Izard S, Kpamou C, March L, Savane I, Barry M, Delaporte E; Postebogui Study Group.
Ebola virus is known since 1976 but only after the 2014 outbreak have research organisations been able to move towards treatments and vaccines. In particular thanks to clinical trials and
Salinas S, Erkilic N, Damodar K, Molès JP, Fournier-Wirth C, Van de Perre P, Kalatzis V, Simonin Y.
Simonin Y, Loustalot F, Desmetz C, Foulongne V, Constant O, Fournier-Wirth C, Leon F, Molès JP, Goubaud A, Lemaitre JM, Maquart M, Leparc-Goffart I, Briant L, Nagot N, Van de Perre P, Salinas S.